Which Neisseria meningitidis serogroup is most prevalent globally?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dominant Meningococcal Serogroup Globally

Serogroup B is the most prevalent Neisseria meningitidis serogroup globally in most developed countries, while serogroup A historically dominated sub-Saharan Africa's meningitis belt, though this has largely disappeared following mass vaccination programs. 1, 2

Geographic Distribution Patterns

European Countries and Developed Nations

  • Serogroup B causes the majority of meningococcal meningitis cases in both children and adults in European countries 1
  • Following successful serogroup C vaccination campaigns in the early 2000s, serogroup B emerged as the dominant strain after virtual elimination of serogroup C disease 1
  • From 2010-2019, serogroup B was the predominant cause of invasive meningococcal disease (IMD) in most countries worldwide 3

Sub-Saharan Africa (Meningitis Belt)

  • Serogroup A was historically the major cause of epidemics in sub-Saharan Africa, with epidemic incidence approaching 1000 per 100,000 population (1% of the population) 1, 4
  • Serogroup A has largely disappeared following mass vaccination programs, representing a major public health success 2
  • Serogroups W and X have emerged as significant contributors in this region post-vaccination 2, 4

Americas

  • Serogroups B, C, and Y each account for approximately one-third of cases in the United States 1
  • Among persons aged >11 years in the U.S., 75% of cases are caused by vaccine-preventable serogroups C, Y, or W-135 1
  • Serogroup Y increased from 2% during 1989-1991 to 37% during 1997-2002 in the United States 1

Recent Epidemiologic Shifts (2010-2019)

Emerging Serogroups

  • Notable increases in serogroups W and Y occurred from 2010-2019 in several regions, highlighting the unpredictable nature of meningococcal disease 3
  • Serogroup W became significant after Hajj pilgrimage outbreaks in 2000, with subsequent endemic disease increases pre-pandemic 2
  • Serogroup Y emerged in the 1990s and prevalence had increased or stabilized from 2010-2018 2

Post-COVID-19 Pandemic Patterns

  • Global IMD declined during the COVID-19 pandemic, followed by resurgences primarily caused by serogroups that were prevalent pre-pandemic 2
  • Resurgences mainly affected unvaccinated age groups, particularly adolescents and young adults 2

Clinical Implications

Vaccine Coverage Considerations

  • Serogroups A, B, C, W, and Y are responsible for the vast majority of IMD cases globally 3
  • Serogroup B vaccines (such as Bexsero/4CMenB) are licensed for protection against serogroup B disease 5
  • Comprehensive vaccination against MenB and MenACWY addresses the predominant circulating serogroups in most developed regions 2

Age-Specific Patterns

  • Highest disease rates occur in infants aged <1 year (9.2/100,000), followed by persons aged 11-19 years (1.2/100,000) 1
  • Among infants, >50% of cases are caused by serogroup B 1
  • Adolescents and young adults demonstrate the highest nasopharyngeal carriage rates, serving as the primary reservoir for transmission 6

Critical Pitfall

The epidemiology of meningococcal disease is highly dynamic and varies substantially by geographic region and time period 4, 3. Clinicians must not assume static serogroup distributions—local surveillance data should guide empiric treatment and vaccination strategies, as global patterns may not reflect regional epidemiology 1, 2.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Guideline

Meningococcal B Disease Vaccination

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6
Guideline

Nasopharyngeal Carriage of Neisseria meningitidis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What first‑line, pregnancy‑safe medications are recommended for nausea and vomiting in a gravida 1, para 0 woman at 8 weeks and 5 days gestation?
What is the Capizzi induction regimen (continuous‑infusion cytarabine 20 mg/m² per hour for 10 days plus idarubicin 12 mg/m² IV on days 1‑3) for older or medically frail adults with acute myeloid leukaemia, and what supportive care and alternative low‑intensity options should be considered?
What is the appropriate starting dose of Suboxone (buprenorphine/naloxone) for an adult with opioid use disorder who is in moderate opioid withdrawal?
If GeneXpert is positive for Mycobacterium tuberculosis but rifampicin resistance is indeterminate, how should I manage the patient?
What is the recommended anticoagulation strategy during pregnancy for patients requiring treatment or prophylaxis of venous thromboembolism, antiphospholipid syndrome, atrial fibrillation, or mechanical heart valves?
What are the most common postoperative complications after parathyroidectomy and how should they be monitored and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question